Several studies have reported elevation of the peptide in ictal and/or interictal phases in medication-free periods of migraine patients [14–38], the reduction of the CGRP levels after abortive and prophylactic treatment [26, 28, 38–44] and the induction of migraine-like headaches when infused in humans [45]. This evidence concerns the gene CALCA and migraine disorder.